上海皓元医药股份有限公司股东减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Shanghai Haoyuan Pharmaceutical Co., Ltd., driven by the shareholder's personal funding needs, which may impact the company's stock performance and investor sentiment [2][3]. Shareholder Holding Situation - Prior to the reduction plan, the shareholder, Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), held 6,909,364 shares, accounting for 3.26% of the company's total share capital [2]. Reduction Plan Details - The shareholder plans to reduce holdings by up to 6,362,959 shares, representing no more than 3% of the total share capital. This includes a maximum of 2,120,986 shares through centralized bidding (up to 1% of total shares) and 4,241,973 shares through block trading (up to 2% of total shares) [3][4]. - The reduction will occur within three months following a 15 trading day period after the announcement [3]. Shareholder's Past Reduction Activity - The shareholder has previously reduced shares, with details available in earlier announcements from February and June 2025 [6]. Shareholder Commitments - The shareholder has made commitments regarding share lock-up and reduction intentions, including a 12-month lock-up period post-IPO and adherence to legal regulations for any future reductions [9][10].